These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

489 related articles for article (PubMed ID: 22437221)

  • 1. Tolerability of concomitant use of selective serotonin reuptake inhibitors or serotonin-norepinephrine reuptake inhibitors and oxymorphone extended release.
    Peniston JH; Hu X; Potts SL; Wieman MS; Turk DC
    Postgrad Med; 2012 Mar; 124(2):114-22. PubMed ID: 22437221
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Factors affecting acceptability of titrated oxymorphone extended release in chronic low back pain - an individual patient analysis.
    Peniston JH; Xiang Q; Gould EM
    Curr Med Res Opin; 2010 Aug; 26(8):1861-71. PubMed ID: 20521870
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Oxymorphone extended release for the treatment of chronic low back pain: a retrospective pooled analysis of enriched-enrollment clinical trial data stratified according to age, sex, and prior opioid use.
    Peniston JH; Gould E
    Clin Ther; 2009 Feb; 31(2):347-59. PubMed ID: 19302907
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A 12-week, randomized, placebo-controlled trial assessing the safety and efficacy of oxymorphone extended release for opioid-naive patients with chronic low back pain.
    Katz N; Rauck R; Ahdieh H; Ma T; Gerritsen van der Hoop R; Kerwin R; Podolsky G
    Curr Med Res Opin; 2007 Jan; 23(1):117-28. PubMed ID: 17257473
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Selective serotonin reuptake inhibitors (SSRIs) and serotonin-norepinephrine reuptake inhibitors (SNRIs) for the prevention of tension-type headache in adults.
    Banzi R; Cusi C; Randazzo C; Sterzi R; Tedesco D; Moja L
    Cochrane Database Syst Rev; 2015 May; 2015(5):CD011681. PubMed ID: 25931277
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A 2-week, multicenter, randomized, double-blind, placebo-controlled, dose-ranging, phase III trial comparing the efficacy of oxymorphone extended release and placebo in adults with pain associated with osteoarthritis of the hip or knee.
    Kivitz A; Ma C; Ahdieh H; Galer BS
    Clin Ther; 2006 Mar; 28(3):352-64. PubMed ID: 16750450
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and safety of OPANA ER (oxymorphone extended release) for relief of moderate to severe chronic low back pain in opioid-experienced patients: a 12-week, randomized, double-blind, placebo-controlled study.
    Hale ME; Ahdieh H; Ma T; Rauck R;
    J Pain; 2007 Feb; 8(2):175-84. PubMed ID: 17145204
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Selective serotonin reuptake inhibitors (SSRIs) and serotonin-norepinephrine reuptake inhibitors (SNRIs) for the prevention of migraine in adults.
    Banzi R; Cusi C; Randazzo C; Sterzi R; Tedesco D; Moja L
    Cochrane Database Syst Rev; 2015 Apr; 4(4):CD002919. PubMed ID: 25829028
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and safety of oxymorphone extended release in chronic low back pain: results of a randomized, double-blind, placebo- and active-controlled phase III study.
    Hale ME; Dvergsten C; Gimbel J
    J Pain; 2005 Jan; 6(1):21-8. PubMed ID: 15629415
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Long-term tolerability and effectiveness of oxymorphone extended release in patients with cancer.
    Slatkin NE; Rhiner MI; Gould EM; Ma T; Ahdieh H
    J Opioid Manag; 2010; 6(3):181-91. PubMed ID: 20642247
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy and tolerability of oxymorphone immediate release for acute postoperative pain after abdominal surgery: a randomized, double-blind, active- and placebo-controlled, parallel-group trial.
    Aqua K; Gimbel JS; Singla N; Ma T; Ahdieh H; Kerwin R
    Clin Ther; 2007 Jun; 29(6):1000-12. PubMed ID: 17692717
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of SSRIs and SNRIs in major depressive disorder: a meta-analysis of head-to-head randomized clinical trials.
    Machado M; Einarson TR
    J Clin Pharm Ther; 2010 Apr; 35(2):177-88. PubMed ID: 20456736
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Trajectory and magnitude of response in adults with anxiety disorders: a Bayesian hierarchical modeling meta-analysis of selective serotonin reuptake inhibitors, serotonin norepinephrine reuptake inhibitors, and benzodiazepines.
    Mendez EM; Mills JA; Suresh V; Stimpfl JN; Strawn JR
    CNS Spectr; 2024 Jun; 29(3):187-196. PubMed ID: 38523533
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Remission, dropouts, and adverse drug reaction rates in major depressive disorder: a meta-analysis of head-to-head trials.
    Machado M; Iskedjian M; Ruiz I; Einarson TR
    Curr Med Res Opin; 2006 Sep; 22(9):1825-37. PubMed ID: 16968586
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Selective serotonin reuptake inhibitors and serotonin-norepinephrine reuptake inhibitors as adjuncts for postoperative pain management: systematic review and meta-analysis of randomised controlled trials.
    Wang L; Tobe J; Au E; Tran C; Jomy J; Oparin Y; Couban RJ; Paul J
    Br J Anaesth; 2022 Jan; 128(1):118-134. PubMed ID: 34756632
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of agomelatine and selective serotonin reuptake inhibitors/serotonin-norepinephrine reuptake inhibitors in major depressive disorder: A meta-analysis of head-to-head randomized clinical trials.
    Huang KL; Lu WC; Wang YY; Hu GC; Lu CH; Lee WY; Hsu CC
    Aust N Z J Psychiatry; 2014 Jul; 48(7):663-71. PubMed ID: 24604920
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Titration with oxymorphone extended release to achieve effective long-term pain relief and improve tolerability in opioid-naive patients with moderate to severe pain.
    Rauck R; Ma T; Kerwin R; Ahdieh H
    Pain Med; 2008 Oct; 9(7):777-85. PubMed ID: 18950436
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A phase 3, multicenter, randomized, double-blind, placebo-controlled, safety, tolerability, and efficacy study of Xtampza ER in patients with moderate-to-severe chronic low back pain.
    Katz N; Kopecky EA; O'Connor M; Brown RH; Fleming AB
    Pain; 2015 Dec; 156(12):2458-2467. PubMed ID: 26262828
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Safety, tolerability, and effectiveness of oxymorphone extended release for moderate to severe osteoarthritis pain: a one-year study.
    McIlwain H; Ahdieh H
    Am J Ther; 2005; 12(2):106-12. PubMed ID: 15767827
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Oxymorphone extended-release tablets relieve moderate to severe pain and improve physical function in osteoarthritis: results of a randomized, double-blind, placebo- and active-controlled phase III trial.
    Matsumoto AK; Babul N; Ahdieh H
    Pain Med; 2005; 6(5):357-66. PubMed ID: 16266356
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 25.